
Nifty Pharma Prediction for Tomorrow, Tuesday 4 August 2026: Index at 21,845 Holds Ground on Defensive Positioning and US Generic Momentum
Nifty Pharma Monday: 21,845 (+0.32%). Day range: 21,680-21,910. Support 21,650-21,700. Resistance 22,050-22,100. Nifty 50: 24,611 (+0.94%).
Updated: 3 Aug 2026 • 4:54 pm
Posted by:

The Nifty Pharma prediction for tomorrow for Tuesday 4 August 2026 is shaped by a historic macro event on Monday: US President Trump confirmed Iran-US peace negotiations, sending Brent crude crashing over 6 percent to $82 and lifting Nifty 50 by 228 points or 0.94 percent to 24,611.50, its first close above 24,600 in six weeks. Nifty Pharma gained 0.32 percent Monday, tracking slightly above the defensive holding pattern. Pharmaceutical companies benefit from non-cyclical domestic demand and a softening dollar that improves rupee realizations on US generic sales. Sun Pharma's 27 percent Q1 net profit growth set a positive benchmark for the entire sector's earnings season. The Nifty Pharma prediction for tomorrow is supported by stable domestic formulations demand growing at 10-12 percent year-on-year, FDA compliance improvements reducing regulatory overhang, and the dollar near 95.59 being supportive for export realizations. Ankit Jaiswal, Senior Research Analyst at Univest, and Kunal Singla, Associate Director at Univest, present the full Nifty Pharma prediction for tomorrow covering technical levels, key triggers and three stocks to watch.
Click Here – Get Free Investment Predictions
Monday Session Data Behind the Nifty Pharma Prediction For Tomorrow
| Indicator | Monday | Change |
|---|---|---|
| Nifty Pharma | 21,845 | +0.32% |
| Day Range | 21,680-21,910 | Session high/low |
| Nifty 50 | 24,611.50 | +228 pts (+0.94%) |
| Bank Nifty | 57,507.80 | +531 pts (+0.93%) |
| India VIX | 11.55 | -4.9% (multi-month low) |
| FII Cash (provisional) | +Rs 918 Cr | Net Buyers |
Technical Levels for the Nifty Pharma Prediction For Tomorrow
| Level | Zone |
|---|---|
| Immediate Support | 21,650-21,700 |
| Support 2 | 21,350-21,400 |
| Strong Support | 20,900-21,000 (50 DMA) |
| Immediate Resistance | 22,050-22,100 |
| Key Resistance | 22,400-22,600 |
Ankit Jaiswal notes that the Nifty Pharma prediction for tomorrow rests on the immediate support at 21,650-21,700 holding during Tuesday's session. Monday's close near the session high for most assets confirms buyers were in control into the 3:30 PM bell, a strong quality signal for the Nifty Pharma prediction for tomorrow. Kunal Singla adds that India VIX at 11.55, its lowest in several months, reduces the probability of a large gap-down reversal, providing a constructive technical environment for the Nifty Pharma prediction for tomorrow.
Key Factors for the Nifty Pharma Prediction For Tomorrow
- Sun Pharma's Q1 FY27 net profit jumping 27 percent with strong India business and US generics performance sets a positive earnings framework for the Nifty Pharma prediction for tomorrow.
- A softening US dollar at 95.59 against the rupee improves export realizations for generic drug companies. Indian pharma's US generic business accounts for 35-40 percent of total revenue for most large companies, directly impacting the Nifty Pharma prediction for tomorrow.
- India's domestic formulations market growing at 10-12 percent year-on-year provides stable base demand insulated from global pharma cycle volatility in the Nifty Pharma prediction for tomorrow.
Stocks to Watch in the Nifty Pharma Prediction For Tomorrow
Univest analysts have flagged three stocks for educational observation in the Nifty Pharma prediction for tomorrow. These are not buy recommendations.
1. Sun Pharma: Trading near Rs 1,778 on Monday. Ankit Jaiswal flags entry zone Rs 1,758-1,772, target Rs 1,828, stop loss Rs 1,730. Sun Pharma is the largest Nifty Pharma constituent with the strongest Q1 FY27 earnings and is the primary directional stock for the Nifty Pharma prediction for tomorrow.
2. Cipla: Trading near Rs 1,645 on Monday. Kunal Singla flags entry zone Rs 1,625-1,640, target Rs 1,695, stop loss Rs 1,598. Cipla's India respiratory franchise and US specialty generics provide diversified pharma exposure in the Nifty Pharma prediction for tomorrow.
3. Apollo Hospitals: Trading near Rs 7,215 on Monday. Ankit Jaiswal flags entry zone Rs 7,150-7,200, target Rs 7,425, stop loss Rs 7,050. Apollo Hospitals captures the domestic healthcare services demand component of the broader Nifty Pharma prediction for tomorrow theme.
Use the Univest Screener to Find Strong Stocks for Tomorrow's Session
Nifty Pharma Prediction For Tomorrow: Trading Strategy
- 21,650-21,700 is the primary support for the Nifty Pharma prediction for tomorrow.
- 22,050-22,100 is the immediate resistance for the Nifty Pharma prediction for tomorrow. Ankit Jaiswal recommends booking here.
- Track Sun Pharma and Cipla open prices Tuesday for the Nifty Pharma prediction for tomorrow directional signal.
- Monitor any US FDA inspection or warning letter announcements that could create stock-specific moves in the Nifty Pharma prediction for tomorrow.
Risks to the Nifty Pharma Prediction For Tomorrow
- Risk-on rotation away from defensive pharma toward cyclicals limiting the Nifty Pharma prediction for tomorrow.
- Dollar recovery reducing US generic export realizations and revising the Nifty Pharma prediction for tomorrow lower.
- US FDA warning letters on Indian manufacturing plants creating sector-wide sentiment headwinds in the Nifty Pharma prediction for tomorrow.
Conclusion
The Nifty Pharma prediction for tomorrow for Tuesday 4 August 2026 shows +0.32% to 21,845 on Monday, with India VIX at a multi-month low of 11.55 and FII returning to net buying at Rs 918 crore. Ankit Jaiswal of Univest identifies 22,050-22,100 as the key resistance for the Nifty Pharma prediction for tomorrow while Kunal Singla considers 21,650-21,700 the most important support to watch Tuesday. Check GIFT Nifty at 9 AM IST, monitor Iran diplomatic updates overnight, and track Bharti Airtel and ONGC Q1 FY27 results in the first hour as the three most critical real-time inputs for the Nifty Pharma prediction for tomorrow.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with NSE (nseindia.com), BSE (bseindia.com) and MCX (mcxindia.com) before investing. Investments are subject to market risk. Educational content only, not investment advice by Univest (SEBI RA INH000013776).
Download the Univest iOS App or Univest Android App for live market data and daily research from SEBI registered analysts.
FAQs on Nifty Pharma Prediction For Tomorrow
What is the Nifty Pharma prediction for tomorrow, Tuesday 4 August 2026?
Ans. The Nifty Pharma prediction for tomorrow is mildly bullish. Nifty Pharma closed Monday at 21,845, up 0.32 percent. Support is 21,650-21,700 and resistance 22,050-22,100 in the Nifty Pharma prediction for tomorrow.
Which analysts prepared the Nifty Pharma prediction for tomorrow?
Ans. Ankit Jaiswal, Senior Research Analyst, and Kunal Singla, Associate Director at Univest, prepared the Nifty Pharma prediction for tomorrow.
How does the US dollar affect the Nifty Pharma prediction for tomorrow?
Ans. A softer dollar at 95.59 improves rupee realizations for generic drug exports to the US market, which accounts for 35-40 percent of large Indian pharma revenues. This is the key exchange rate impact on the Nifty Pharma prediction for tomorrow.
What is Nifty Pharma support and resistance for the prediction for tomorrow?
Ans. Support is 21,650-21,700 and 21,350-21,400. The 50 DMA at 20,900-21,000 is the medium-term floor. Resistance is 22,050-22,100 and 22,400-22,600 in the Nifty Pharma prediction for tomorrow.
What stocks are watched in the Nifty Pharma prediction for tomorrow?
Ans. Sun Pharma (largest constituent, best Q1 FY27 growth), Cipla (diversified India and US portfolio) and Apollo Hospitals (domestic healthcare services) are the three stocks in the Nifty Pharma prediction for tomorrow.
Recent Articles

Baroda BNP Paribas Equity Savings Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
3 August 2026

Baroda BNP Paribas Balanced Advantage Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
3 August 2026

Baroda BNP Paribas Yield Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
3 August 2026

Baroda BNP Paribas Business Cycle Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
3 August 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Baroda BNP Paribas Equity Savings Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Balanced Advantage Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Yield Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Business Cycle Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Value Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Popular this week
Baroda BNP Paribas Equity Savings Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Balanced Advantage Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Yield Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Business Cycle Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Value Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





